Source: Virtual Congress 2021 – Novel insights into the pathogenesis of chronic lung diseases



Rating:

Share or cite this content

Citations should be made in the following way:
A. Nizamova (Ufa, Russian Federation), G. Gimalova (Ufa, Russian Federation), Z. Abdullin (Ufa, Russian Federation), E. Khusnutdinova (Ufa, Russian Federation). The analysis of CHEK2 gene mutation in small cell lung cancer. 662

Member's Comments

No comment yet.

Related content which might interest you: p53 gene mutations in lung cancer in Korean Source: Eur Respir J 2005; 26: Suppl. 49, 327s Year: 2005 Arg72Pro P53 gene polymorphism is associated with P53 mutations in non-small cell lung cancer (NSCLC) patients Source: Eur Respir J 2004; 24: Suppl. 48, 78s Year: 2004 Investigation of a relationship between NF-KB1A gene polymorphism and non small cell lung cancer (NSCLC) Source: Annual Congress 2012 - New biomarkers for lung cancer Year: 2012 Arg72Pro and GSTM1 gene polymorphisms increase the risk of non small cell lung cancer (NSCLC) Source: Eur Respir J 2005; 26: Suppl. 49, 92s Year: 2005 The correlation between p53 gene mutation and the expression of tumor drug resistance genes in lung cancer and its clinical significance Source: Annual Congress 2005 - Prognostic factors in lung cancer Year: 2005 Overall survival analysis and characterization of an EGFR mutated non small cell lung cancer (NSCLC) population Source: International Congress 2017 – Lung cancer: clinically relevant aspects of epidemiology, co-morbidities, metastasised disease and follow-up Year: 2017 Prognostic value of TP53, KRAS and EGFR mutations in nonsmall cell lung cancer: the EUELC cohort Source: Eur Respir J 2012; 40: 177-184 Year: 2012 Characteristics and prognostic relevance of p53 gene mutations in Polish non small cell lung cancer (NSCLC) patients Source: Eur Respir J 2005; 26: Suppl. 49, 92s Year: 2005 Germ-line exon 21 EGFR mutations, V843I and P848L, in nonsmall cell lung cancer patients Source: Eur Respir Rev 2014; 23: 390-392 Year: 2014 Arg72Pro P53 gene polymorphism as a predisposing factor for non-small cell lung cancer (NSCLC) development Source: Eur Respir J 2004; 24: Suppl. 48, 78s Year: 2004 Evaluation of EGFR mutations and ERCC2 polymorphisms in treatment of non-small cell lung cancer Source: Annual Congress 2005 - Chemotherapy and palliative care Year: 2005 Association of polymorphism of the human nm23-H1 gene (NME1) with susceptibility to and severity of non-small cell lung cancer Source: Annual Congress 2007 - Diagnosis and prognosis in thoracic oncology Year: 2007 Polymorphism in GSTM1, GSTT1, p53 and CCR5 genes and lung cancer progression: relation to p53 and Ki-67 protein expression in tumors of non-small cell lung cancer patients Source: Eur Respir J 2006; 28: Suppl. 50, 810s Year: 2006 Genotyping single-nucleotide polymorphisms (SNP) in ERCC1, XPD, XRCC1, XRCC3 and MDR-1 and CCND-1 genes for response and toxicity prediction in chemotherapy of non small cell lung cancer (NSCLC) Source: Annual Congress 2007 - Biology in thoracic oncology Year: 2007 In silico gene expression analysis of small cell lung cancer Source: Annual Congress 2010 - The role of biomarkers in lung cancer Year: 2010 Association of -93G®A polymorphism in the hMLH1 gene with susceptibility to and prognosis of non-small cell lung cancer in Taiwan Source: Eur Respir J 2006; 28: Suppl. 50, 151s Year: 2006 K-RAS oncogenic mutations in patients with nonsmall cell lung cancer Source: Annual Congress 2007 - Biology of thoracic malignancies Year: 2007 Polymorphisms A1026G and G369C of CDKN1A/p21 and p53 genes in lung cancer Source: Annual Congress 2011 - Lung cancer: molecular pathology and functional genomics Year: 2011 Clinical relevance of p53 and K-ras mutations in nonsmall cell lung cancer (NSCLC) Source: Eur Respir J 2001; 18: Suppl. 33, 230s Year: 2001